Abstract
Emerging studies have revealed that N6-methyladenosine modification is involved in the development of various cancers. However, the m6A modification pattern of endometrioid ovarian cancer (EOC) has not been demonstrated. In the present study, high-throughput sequencing combined with methylated RNA immunoprecipitation (MeRIP-seq) and RNA sequencing were used to obtain the transcriptome-wide m6A modifications of endometrioid ovarian cancer for the first time. The roles of methyltransferase-like 3 (METTL3) in EOC cell line COV362 were explored. In total, 39,237 m6A-modified peaks related to 17,082 genes were identified in the EOC group, and 52,848 m6A peaks representing 19,349 genes were detected in endometriosis group. Functional enrichment analysis revealed that m6A enriched genes were associated with tight junctions, cell adhesion molecules, platinum drug resistance, adherens junction, and more. METTL3 knockdown in the COV362 cells significantly decreased cell proliferation, promoted cell apoptosis, and induced cell cycle arrest at the G0/G1 phase. Our study presented the transcriptome-wide m6A modifications of endometrioid ovarian cancer for the first time and revealed various differentially expressed genes with methylated m6A modifications. This study may provide new directions for in-depth research of the underlying molecular mechanisms and signaling pathways of EOC development and progression.
Highlights
Ovarian cancer is the third most common cancer worldwide and it has the highest mortality rate in females
Three pairs of human endometrioid ovarian cancer (EOC) and endometriosis samples were selected for MeRIP-seq and RNA sequencing assays
The results indicate the significant difference in global m6A distribution in EOC and Ovarian endometriosis (OE) groups
Summary
Ovarian cancer is the third most common cancer worldwide and it has the highest mortality rate in females. According to the Global Cancer Statistics, there were 313,959 new cases diagnosed and 207,252 women died of the disease in 2020 [1]. Epithelial ovarian cancer is the most common type of ovarian cancer. Endometrioid ovarian cancer (EOC) accounts for 10-15% of epithelial ovarian cancer [2, 3]. Ovarian endometriosis (OE) is associated with EOC and is commonly considered a direct precursor lesion to endometrioid and clear cell ovarian cancer types [4]. Most of the patients m6A Modification in Endometrioid Ovarian Cancer with EOC are diagnosed at an early stage with good prognosis. Some patients still have early recurrence and metastasis with poor prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
